Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
MASLD and MASH can lead to liver fibrosis, cirrhosis and liver cancer.
However, only 24% of people with hepatocellular carcinoma received direct-acting antiviral therapy.
An increase in fatty liver disease could double liver cancer cases and nearly triple the need for transplants by 2050.
Hepatocellular carcinoma among people with HCV fell after the debut of direct-acting antivirals, but cases are rising for other groups.
In 2022, fatty liver disease accounted for nearly a quarter of all liver cancer cases on the transplant waiting list.
About 40% of people worldwide are not aware that viral hepatitis is a leading cause of liver cancer.
Men, people with obesity and people who smoke are more likely to develop NAFLD.
Human papillomavirus and hepatitis B vaccines lower the risk of developing cancer.
Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.
Results in cell and mouse studies may have implications for the development of a new class of anticancer drugs.
People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.
People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.
Experts predict that more than a million people could die from liver cancer worldwide in 2040.
People who achieved SVR two or more years ago were less likely to develop hepatocellular carcinoma than those cured more recently.
Imjudo plus Imfinzi improved overall survival compared with standard targeted therapy for hepatocellular carcinoma.
People with hepatocellular carcinoma had improved survival after the advent of direct-acting antiviral therapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.